Nuvalent's zidesamtinib nears Sept. 18 FDA decision on breakthrough-tagged ROS1 NSCLC drug
The pending decision covers TKI pre-treated ROS1-positive NSCLC, a setting where zidesamtinib holds breakthrough and orphan designations and the feeding trial itself remains open and recruiting.
Executive Summary
- Nuvalent is approaching a fixed FDA action date on its application for zidesamtinib in ROS1-positive NSCLC patients who have already been treated with prior ROS1-targeted therapy.
- The drug carries designations that reflect an FDA view of unmet need in this post-TKI setting, a favorable but non-predictive backdrop heading into the decision.
- The trial supporting the application has not closed out. It remains in active recruitment with an extended completion timeline, a fact that frames the regulatory submission as built on an evolving rather than fully matured dataset.
- The ROS1-targeted field in NSCLC is thin, with no other industry-sponsored trial sharing both the same target and mechanism class in active development, leaving zidesamtinib without a direct in-class comparator at this stage.
The catalyst
Nuvalent Inc. is awaiting an FDA decision on zidesamtinib (NVL-520) in patients with ROS1 mutation-positive NSCLC who have progressed on prior ROS1 TKIs, with a target action date of September 18, 2026. The application draws on data from ARROS-1 (NCT05118789), a Phase 1/2 trial testing zidesamtinib across ROS1-rearranged NSCLC and other solid tumors. The trial's primary endpoints are Objective Response Rate in Phase 2, alongside Recommended Phase 2 Dose and Maximum Tolerated Dose from the Phase 1 dose-finding portion, the standard endpoint structure for a combined dose-finding and efficacy-expansion design in oncology. Royalty+1Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to ...Dec 16, 2025A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)NCT05118789
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Regulatory signals ahead of the decision
Zidesamtinib holds Breakthrough Therapy Designation and Orphan Drug Designation for ROS1-positive NSCLC in patients previously treated with two or more ROS1 TKIs, both granted in 2024. Nuvalent said in December 2025 that zidesamtinib "is currently undergoing review by the U.S. Food and Drug Administration and has an action date of September 18, 2026 for TKI pre-treated patients". These designations reflect an FDA view of unmet need in a heavily pre-treated population; they do not by themselves indicate how the agency will rule on the pending application. RoyaltyRoyalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to ...Dec 16, 2025
The trial behind the filing
ARROS-1 remains in Recruiting status, with an anticipated enrollment of 359 patients across 14 countries, and its primary completion date shifted from October 31, 2025 to December 31, 2027 as recorded in an October 2025 registry update. That extension reflects the trial's continued enrollment of additional cohorts, including TKI-naive patients in the Phase 2 portion, rather than a closeout of the population supporting the pending pre-treated-patient submission. The trial has logged two enrollment increases since 2022, moving from 246 to 359 anticipated participants, changes that fall within the routine range for an expanding multi-cohort design and are not flagged by the operational enrollment threshold used to screen for outsized shifts. NCT05118789A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)NCT05118789
The competitive setting
No other industry-sponsored trial in the competitive scan shares both the ROS1 target and a ROS1-kinase-inhibitor mechanism class with zidesamtinib in active NSCLC development; the nearest listed comparators, including KRAS G12C, EGFR, and HER2-directed programs from sponsors such as Merck, Roche, and Boehringer Ingelheim, work through different targets within the same small-molecule modality. Pfizer's crizotinib and lorlatinib appear only through expanded-access protocols rather than as active ROS1-targeted development programs. That leaves zidesamtinib without a direct in-class comparator in the current field, a structural sparsity that raises the informational weight of this single regulatory decision for how the ROS1-positive, TKI pre-treated segment gets treated going forward.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.